GLP-1s and menopause: what the trials say about women in midlife

Reviewed 13 sourcesPublished by PepVault

GLP-1s in menopause: tirzepatide weight loss by menopause stage, semaglutide with hormone therapy, the pill, bone and fractures, and the hot-flash trials.

A blonde woman in a plum crop top holding a side plank on a wooden deck
Last reviewed
Sources
13
Questions
7
Compounds
2

The short answer

In the trials, menopause did not blunt GLP-1 weight loss. In a post hoc analysis of SURMOUNT-1, women on tirzepatide 15 mg lost 23 to 26% of their body weight at 72 weeks whether they were before, during or after menopause, against 2 to 3% on placebo. Two Mayo Clinic chart reviews, one per drug, found more loss in women also taking menopause hormone therapy.

Every number checked at its primary source · · 13 sources · How we research

Evidence: Post hoc analyses of randomised phase 3 trials (SURMOUNT-1, -3 and -4) for tirzepatide, observational clinic studies for semaglutide and tirzepatide, FDA label data, a meta-analysis of placebo-controlled trials of mostly older GLP-1s, and two 2026 reviews; no randomised trial of a GLP-1 for menopause symptoms has reported. Tirzepatide (Zepbound) and semaglutide (Wegovy) are FDA-approved for weight management.

A blonde woman in a plum crop top holding a side plank on a wooden deck

Does tirzepatide work as well after menopause?

Yes, nearly as well. Researchers, most of them Eli Lilly employees, went back through three SURMOUNT trials and sorted 2,542 women without diabetes into premenopause, perimenopause (the transition years, when periods become irregular) and postmenopause1. The trials had not recorded menopause, so this is a post hoc analysis: one done after the trial, on groups it was not designed to compare. Most women were placed by age alone: under 45 counted as premenopausal, 45 to 54 as perimenopausal unless something showed otherwise, and 55 or older as postmenopausal1.

In SURMOUNT-1, the largest of the three, the groups averaged 34, 45 and 58 years old. At week 72 on tirzepatide 15 mg the result barely moved across them. These are the abstract's figures; the paper's results text gives the tirzepatide range as 24 to 26%1:

SURMOUNT-1, week 72PremenopausePerimenopausePostmenopause
Women in the analysis (all arms)697429581
Body weight, tirzepatide 15 mg vs placebo−26% vs −2%−23% vs −3%−23% vs −3%
Waist, tirzepatide 15 mg vs placebo−22 cm vs −4 cm−20 cm vs −5 cm−20 cm vs −4 cm
Reached a low-risk waist-to-height ratio (BMI under 35)52% vs 6%30% vs 0%30% vs 0%

The waist matters here. Around menopause fat tends to move to the middle, and the authors chose the waist-to-height ratio because it tracks that central fat better than BMI does; 0.49 or below counts as low risk1. Across all three groups, 97 to 98% of women on tirzepatide lost at least 5% of their weight, against 29 to 33% on placebo, and SURMOUNT-3 and SURMOUNT-4 showed the same pattern1. Women past menopause started with more high blood pressure, high cholesterol and prediabetes: half of them had prediabetes, against 29% before menopause1.

PepVault's weight log charts the scale week by week, and a body check-in records your waist, the measure this analysis followed. Track your weight in PepVault

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault's weight log charts the scale week by week, and a body check-in records your waist, the measure this analysis followed.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What about semaglutide in women after menopause?

Semaglutide has no published STEP trial analysis by menopause stage that we could find. Wegovy's label states only that weight fell irrespective of age, sex, race, ethnicity and starting BMI5. The menopause-specific evidence is observational: studies of people treated in ordinary care, with no placebo group.

The best known is from the Mayo Clinic. It looked back at 106 postmenopausal women treated with semaglutide for at least three months, 16 of whom were also on menopause hormone therapy (estradiol as a patch or a pill, with a progestogen if they still had a uterus)2. The women on hormone therapy lost more at every checkpoint2:

Months on semaglutideWith hormone therapy (16 women)Without (90 women)
37%5%
613%9%
915%10%
1216%12%

The gap held after the authors adjusted for dose and other factors, and it was the same whether the estradiol came as a patch or a pill2. A Spanish clinic study found that four months of semaglutide 1 mg took off about 5 to 6% of body weight in postmenopausal and premenopausal women alike, with similar fat loss3.

Does hormone therapy make a GLP-1 work better?

Possibly, and the signal now comes from both drugs. A second Mayo Clinic chart review followed 120 postmenopausal women on tirzepatide for a year or more, 40 of them on hormone therapy; by Mayo's account of the paper, those on hormone therapy lost about 35% more weight13. Both studies are observational, and women who take hormone therapy can differ from those who don't in ways a chart review cannot see; both author groups call for prospective studies213. The Spanish Menopause Society's 2026 position statement reads the link as hypothesis-generating and says it should not be a reason to start hormone therapy only to lose more weight9. Hormone therapy is chosen for menopause symptoms and bone, on its own merits.

A direct test is under way. A randomised trial at University Hospital Bern in Switzerland is giving 96 early postmenopausal women with prediabetes or type 2 diabetes an estradiol patch (with progesterone if they have a uterus), semaglutide up to 1 mg, or both, for 12 weeks. Long-term blood sugar (HbA1c) is the main measure, with weight, body fat and hot flashes among the others. Its estimated primary completion is December 202612.

Do GLP-1s help hot flashes?

Nobody knows yet: no randomised trial has reported on it. Hot flashes and night sweats, called vasomotor symptoms, were not measured in the big weight trials. The first placebo-controlled test is a Mayo Clinic pilot that started in April 2026: 40 postmenopausal women with obesity, tirzepatide or placebo for 24 weeks, with how often and how hard the hot flashes come as the main measures. Its estimated primary completion is September 202711. The Bern trial above also counts hot flashes, as a secondary measure12.

The reason to hope is indirect: in studies of midlife women, more body fat goes with more hot flashes, a link the SURMOUNT authors cite1. The one direct report points the other way, and it is a single case: a 51-year-old on oral estradiol whose hot flashes and mood worsened while her semaglutide dose was being raised, and settled when the increases were slowed7.

Commonly reported: the waist shrinking along with the scale, evening hunger going quiet, and a split on hot flashes, with some women saying they eased as weight came off and others noticing no change.

Can a GLP-1 affect the pill or oral HRT?

Tirzepatide can, for a few weeks at a time. It slows how fast the stomach empties, most of all after the first dose, and that changes how pills are absorbed. With a single 5 mg dose, peak levels of a combined birth-control pill's hormones fell 55 to 66%, and total exposure fell 20 to 23%4. So Zepbound's label tells women on an oral contraceptive to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase; hormonal methods that are not taken by mouth should not be affected4. Perimenopause still counts here: until menopause is confirmed, pregnancy is possible, and the labels advise stopping semaglutide at least 2 months before a planned pregnancy and stopping tirzepatide once a pregnancy is known45.

Semaglutide's label lists ethinyl estradiol and levonorgestrel, two pill hormones, among the drugs whose levels showed no clinically significant change with it5. For the progestogens taken by mouth in menopause hormone therapy, no interaction study with tirzepatide exists; a 2026 review calls an effect plausible but unproven, and most likely in the start and step-up weeks6. The one report with semaglutide is the oral estradiol case above, and in the Mayo semaglutide study women on estradiol pills lost as much as those on patches27. Patches and gels skip the stomach altogether.

What happens to muscle and bone?

Menopause already speeds the loss of muscle and bone, and a 2026 Mayo Clinic review names that as the main concern for midlife women on these drugs10. Lean mass falls roughly in step with the weight lost, often with better physical function reported, but few trials have measured strength, and bone results so far are inconsistent10. How much of the loss is muscle, and what protects it, is covered in our guide to muscle on a GLP-1.

Bone has one hard number, from Wegovy's label. In SELECT, the heart-outcomes trial in adults with established cardiovascular disease and overweight or obesity, more hip and pelvis fractures were reported on Wegovy than on placebo in women: 1% (24 of 2,448) against 0.2% (5 of 2,424). The gap was also seen in people 75 and older5. A 2026 meta-analysis of placebo-controlled trials found a small drop in spine bone density, about 0.02 g/cm², and no change at the hip over 12 to 52 weeks; 11 of its 12 trials used older GLP-1s, the other semaglutide 1 mg, and none tested semaglutide 2.4 mg or tirzepatide8.

The menopause society's statement pairs the drug with resistance training, enough protein and a check on fracture risk9. Bone density is measured with a DXA scan, the low-dose X-ray the bone trials used8.

PepVault sets a daily protein target from your weight and logs meals by photo, so the protein half of that advice is easy to keep count of. Track your food in PepVault

When to get help A fall that leaves pain in the hip or groin, or makes it hard to stand or walk, is a reason to be seen the same day.

What do the trials not tell us yet?

  • Menopause stage was assigned afterwards, mostly by age, so some women in the perimenopause group may have been placed wrongly1.
  • The tirzepatide analysis was funded by Lilly and mostly written by its staff, and reports only the 15 mg or highest tolerated dose against placebo1.
  • The hormone therapy finding comes from two chart reviews in one clinic system, 16 and 40 women on hormone therapy, with no randomisation213.
  • No trial has finished on hot flashes, sleep or mood with a GLP-111.
  • Fracture data for tirzepatide and for the newer doses are thin, and the bone trials so far were short810.

What the evidence does show is clear enough to act on: the weight comes off after menopause much as it does before, the waist follows, and the questions worth asking a prescriber are about bone, muscle and any oral hormones taken alongside.

Track it in the app

Sources

  1. Tchang BG, Mihai AC, Stefanski A, et al. Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. Obesity (Silver Spring). 2025;33(5):851-860. PubMed 40074721
  2. Hurtado MD, Tama E, Fansa S, et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause. 2024;31(4):266-274. PubMed 38446869
  3. Nicolau J, Blanco-Anesto J, Bonet A, et al. Effectiveness of low doses of semaglutide on weight loss and body composition among women in their menopause. Metab Syndr Relat Disord. 2025;23(1):70-76. PubMed 39761057
  4. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information (DailyMed, SPL version 40, revised 08/2026): sections 7, 8.3 and 12.3. dailymed.nlm.nih.gov
  5. Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information (DailyMed, SPL version 19, revised 06/2026): sections 6.1 (fractures), 8.3, 12.3 and 14. dailymed.nlm.nih.gov
  6. Viana DPDC, Invitti AL, Jacobsen L, Schor E. Tirzepatide and oral progestogens: a hypothesis-generating review of a biologically plausible pharmacokinetic interaction in gynaecologic disease control and menopausal hormone therapy. Maturitas. 2026;214:109116. PubMed 42721915
  7. Parker AE. Worsening vasomotor symptoms in the setting of estradiol and semaglutide: a case report. Menopause. 2025;32(12):1168-1170. PubMed 40729307
  8. Safargar M, Ahmadi N, Prabahar K, et al. The effect of glucagon-like peptide-1 receptor agonists on bone metabolism: a systematic review and meta-analysis of randomized placebo-controlled trials of predominantly first-generation agents. Bone. 2026;215:118160. PubMed 42971377
  9. Sánchez-Prieto M, Romero-Domínguez M, Orozco R, et al. Incretin-based therapies in peri- and postmenopausal women with obesity: an expert position statement from the Spanish Menopause Society. Maturitas. 2026;213:109101. PubMed 42664617
  10. Castaneda R, Pavlov K, Shufelt CL, Faubion SS. Incretin-based therapies in menopause: current landscape. Maturitas. 2026;215:109159. PubMed 42933336
  11. Mayo Clinic. The effect of tirzepatide on menopausal vasomotor symptoms and biological aging in post-menopausal women with obesity: a pilot study (NCT07218445). ClinicalTrials.gov. clinicaltrials.gov
  12. Bally L (sponsor-investigator). Effects of combined menopausal hormone therapy and GLP-1 receptor agonist therapy on glucose and energy homeostasis in early postmenopausal women with or at risk of diabetes (NCT06715514). ClinicalTrials.gov. clinicaltrials.gov
  13. Castaneda R, Bechenati D, Tama E, et al. The role of menopause hormone therapy in modulating tirzepatide-associated weight loss in postmenopausal women with overweight or obesity: a retrospective cohort study. Lancet Obstet Gynaecol Womens Health. 2026;2(2):e118-e128. doi.org

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo